NEW YORK (GenomeWeb) – Ginkgo Bioworks announced today that it has raised $275 million in series D financing.

The Boston-based synthetic biology company will use the proceeds to grow Bioworks3, its new organism foundry, and to expand into new markets such as pharmaceuticals and agriculture.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.